Clinical trials during the prodromal stage of schizophrenia [6]

American Journal of Psychiatry

Volumn 162, Issue 7, 2005, Pages 1387-

  Addington, Jean ^a   Addington, Donald ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RISPERIDONE;

BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HEALTH CARE ACCESS; HIGH RISK POPULATION; HUMAN; LETTER; MAJOR CLINICAL STUDY; PATIENT SELECTION; PRIORITY JOURNAL; PSYCHOSIS; RISK ASSESSMENT; SAMPLE SIZE; SCHIZOPHRENIA;

EID: 21344463795     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.162.7.1387     Document Type: Letter

References (2)

1. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, Germano D, Bravin J, McDonald T, Blair A, Adlard S, Jackson H: Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002; 59:921-928
2. McGlashan TH, Zipursky RB, Perkins DO, Addington J, Miller TJ, Woods SW, Hawkins KA, Hoffman R, Lindborg S, Tohen M, Breier A: The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis, I: study rationale and design. Schizophr Res 2003; 61:7-18